G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder

British Journal of Cancer

Volumn 80, Issue 8, 1999, Pages 1175-1184

  Niehans, G A ^a   Kratzke, R A ^a   Froberg, M K ^a   Aeppli, D M ^a   Nguyen, P L ^a   Geradts, J ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bladder neoplasms; Cyclin D1; p16(1NK4); p53; Retinoblastoma protein

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYSTECTOMY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CYCLINS; FEMALE; G1 PHASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0033028095     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6990483     Document Type: Article

References (54)

1. Aagaard L, Lukas J, Bartkova J, Kjerulff A-A, Strauss M and Bartek J (1995) Aberrations of p16INK4 and retinoblastoma tumour-suppressor genes occur in distinct sub sets of human cancer cell lines. Int J Cancer 61: 115-120
2. American Joint Committee on Cancer (1992) Manual for Staging of Cancer, 4th edn, pp. 195-200. Lippincott: Philadelphia
3. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J and Bartek J (1996) The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56; 5475-5483
4. Bringuier PP, Tamimi Y, Schuuring E and Schalken J (1996) Expression of cyclin D1 and EMS1 in bladder tumours: relationship with chromosome 11q13 amplification. Oncogene 12: 1747-1753
5. Cordon Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z and Reuter VE (1992) Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84: 1251-1256
6. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang Z-F, Rosai J, Reuter VE and Pellicer A (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56: 347-353
7. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi S-R, Tran Q-C, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG and Benedict WF (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58: 1090-1094
8. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAFL a potential mediator of p53 tumor suppression. Cell 75: 817-825
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA and Cote RJ (1994) Accumulation of nuclear p53 and tumour progression in bladder cancer. N Engl J Med 331: 1259-1264
10. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M and Levine AJ (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539
11. Geradts J, Kratzke RA, Niehans GA and Lincoln CE (1995) Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/ multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4a in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 55: 6006-6011
12. Geradts J, Kratzke RA, Crush Stanton S, Wen SF and Lincoln CE (1996) Wild-type and mutant retinoblastoma protein in paraffin sections. Mod Pathol 9: 339-347
13. Gilleu C, Smith P, Gregory W, Richards M, Millis R, Peters G and Barnes D (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer (Pred Oncol) 69: 92-99
14. Glick SH, Howell LP and White RWD (1996) Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 155: 1754-1757
15. Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, Skolnick M, Cordon-Cardo C and Kamb A (1995) Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 146: 1199-1206
16. Harbour JW, Lai S-L, Whang-Peng J, Gazdar AF, Minna JD and Kaye FJ (1988) Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353-357
17. Horowitz JM, Park S-H, Bogenmann E, Cheng J-C, Yandell DW, Kaye FJ, Minna JD, Dryja TP and Weinberg RA (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumour cells. Proc Natl Acad Sci USA 87: 2775-2779
18. Jahnson S, Risberg B, Karlsson MG, Westman G, Bergström R and Pedersen J (1995) p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 28: 135-142
19. Jiang W, Zhang Y-J, Kahn SM, Hollstein MC, Santella RM, Lu S-H, Harris CC, Montesano R and Weinstein IB (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90: 9026-9030
20. Kotelnikov VM, Coon JS IV, Mundle S, Kelanie S, LaFollette S, Taylor S IV, Hutchinson J, Panje W, Caldarelli DD and Preisler HD (1997) Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 3: 95-101
21. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J and Kaye FJ (1995) Immunohistochemical analysis of the p16-INK4a cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 87: 1870-1875
22. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA and Geradts J (1996) Rb and p16INK4a expression in resected non-small-cell lung tumours. Cancer Res 56: 3415-3420
23. Lee CCR, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, Ikemoto S, Nakatani T, Wada S, Kishamoto T and Fukushima S (1997) Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 79: 780-789
24. Li Y, Nichols MA, Shay JW and Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54: 6078-6082
25. Lipponen PK (1993) Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 53: 365-370
26. Lipponen PK and Liukkonen TJO (1995) Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol 121; 44-50
27. Logothetis CJ, Xu H-J, Ro JY, Hu S-X, Sahin A, Ordonez N and Benedict WF (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84: 1256-1261
28. Lukas J, Aagaard L, Strauss M and Bartek J (1995a) Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 55: 4818-4823
29. Lukas J, Bartkova J, Rohde M, Strauss M and Bartek J (1995b) Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15: 2600-2611
30. Lukas J, Parry D, Aagard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J (1995c) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503-506
31. Medema RM, Herrera RE, Lam F and Weinberg RA (1995) Growth suppression by p16-ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92: 6289-6293
32. Nguyen PL, Swanson PE, Jaszez W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J and Niehans GA (1994) Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: A multivariate survival analysis. Am J Clin Pathol 101: 166-176
33. Okamoto A, Demetrick DJ, Spitlare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Greenblatt MS, Serrano M, Shiseki M, Yokota J, Beach DH and Harris CC (1994) p16-INK4 mutations and altered expression in human tumors and cell lines. Cold Spring Harbor Symp Quant Biol 59: 49-57
34. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang Z-E Beach D and Cordon-Cardo C (1995) Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87: 1524-1529
35. Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ (1994) Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378
36. Packenham JP, Taylor JA, Anna CH, White CM and Devereux T (1995) Homozygous deletions but no sequence mutations in ending regions of p15 or p16 in human primary bladder tumours. Mol Carcinogen 14: 147-151
37. Parry D, Bates S, Mann DJ and Peters G (1995) Lack of cyclin D-cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14: 503-511
38. Resnick JM, Cherwitz D, Knapp D, Uhlman D and Niehans GA (1995) A microwave method that enhances detection of aberrant p53 expression in formalin-fixed. paraffin-embedded tissues. Arch Pathol Lab Med 119: 360-366
39. Rosai J (1996) Ackerman's Surgical Pathology. 8th edn, pp. 1197-1201, Mosby: St Louis
40. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon H-E, Komoto Y, Oue T, Kusafuka T, Okada A and Mutsuda H (1996) Inversely correlated expression of p16 and Rb protein in non-small-cell lung cancers: an immunohistochemical study. Int J Cancer 65: 442-445
41. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfeld J, Fair WR, Herr HW and Reuter VE (1993) Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85: 53-59
42. Schauer IE, Siriwardana S, Langan TA and Sclafani RA (1994) Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 91: 7827-7831
43. Schutte M, Hiuban RH, Geradts J, Maynard R, Hilgeis W, Rahindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE and Herman JG (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57: 3126-3130
44. Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition nf cyclinD/CDK4. Nature 366: 704-707
45. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ and Rollins BJ (1995) Reciproca Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509
46. Shin KY, Kong G, Kim WS, Lee TY, Woo YN and Lee JD (1997) Overexpression of cyclin D1 correlates wilh early recurrence in superficial bladder cancers. Br J Cancer 75: 1788-1792
47. Strauss M, Lukas J and Bartek J (1995) Unrestricted cell cycling and cancer. Nature Med 1: 1245-1246
48. Tam SW, Theodoras AM, Shay JW, Draetta GF and Pagano M (1994) Differential expression and regulation of cyclin D1 protein in normal and tumour human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene 9: 2663-2674
49. Tétu B, Fradei Y, Allard P, Veilleux C, Roberge N and Bernard P (1996) Prevalence and clinical significance of HER-2/ncu, p53 and Rb expression in primary superficial bladder cancer. J Urol 155: 1784-1788
50. Tsao H, Benoit E, Sober AJ, Thiele C and Haluska FG (1998) Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase 4 gene. Cancer Res 58: 109-113
51. Ueki K, Ono Y, Henson JW, Elird JT, von Deimling A and Louis DN (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56: 150-153
52. Vet JAM, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FMJ and Schalken JA (1995) Comparison of p53 protein overexpression with p53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest 73: 837-843
53. Williamson MP, Elder PA, Shaw ME, Devlin J and Knowles MA (1995) p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4: 1569-1577
54. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N and Dracopoli NC (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97-99